Information Provided By:
Fly News Breaks for May 24, 2017
NBIX
May 24, 2017 | 08:40 EDT
BMO Capital analyst M. Ian Somaiya recommends buying Neurocrine on weakness after mixed data for the company's Ingrezza in pediatric Tourette's was reported. The analyst says that the data was sufficient to justify the launch of Phase 2b trials, and he believes that the company could obtain a licensing deal in Europe for the drug. He keeps a $75 price target and an Outperform rating on the stock.
News For NBIX From the Last 2 Days
There are no results for your query NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.